Document:

Exhibit 10.1

 

EXCLUSIVE
LICENSE AGREEMENT

This EXCLUSIVE LICENSE AGREEMENT (“Agreement”),
is entered into by and between the SPINAL RESOURCES INC., a Florida corporation (hereinafter referred to as “LICENSOR”)
and OZOP SURGICAL CORP., a Nevada corporation (hereinafter referred to as “LICENSEE”) to be effective August 23, 2019
(the “Effective Date”).

WITNESSETH:

WHEREAS, LICENSOR has the right to grant
licenses relating to the products listed on Schedule A (the “Licensed Products”);

WHEREAS, LICENSEE wishes to obtain an
exclusive right and license to and offer for sale the Licensed Products for commercial use in accordance with the terms and conditions
set forth below.

NOW, THEREFORE, in consideration of
the mutual covenants and promises set forth herein and for other good and valuable consideration, the receipt and legal sufficiency
of which is hereby acknowledged by the parties, the parties agree as follows:

1.00 DEFINITIONS

For the purposes of this Agreement,
the following terms shall have the meanings given below:

1.01. “Effective Date” shall
be the date set forth in the introductory paragraph.

1.02. “Field” shall mean
field of use for the Licensed Products. For purposes of this Agreement, the Fields are spine and related surgical procedures.

1.03. “Licensed Products”
shall mean any product set forth on Schedule A.

1.04. “Licensor Information”
shall mean any and all materials, technical information, data, know-how, inventions, processes and other information relating to
the Licensed Products that are in the possession or control of LICENSOR as of the Effective Date of this Agreement.

1.05. “Net Sales” shall
mean the gross sales of Licensed Product(s) that are produced, processed or sold; and all products produced, processed or sold
through the use of Licensed Process(es) by LICENSEE and sublicensees to or for any party, as and when received by LICENSEE or sublicensees
less (i) customer returns and adjustments and (ii) price allowances and trade discounts actually granted to customers.

1.06 “Process” shall mean
any process derived from the Licensed Products.

1.07. “Service” shall mean
any service derived from the Licensed Products and based on patent rights or Licensor Information that is performed and sold by
LICENSEE.

2.01. LICENSOR hereby grants to LICENSEE,
and LICENSEE hereby accepts from LICENSOR, as of the Effective Date of this Agreement, the exclusive nontransferable, nonassignable
right and license to use, sell, have sold and offer for sale the Licensed Products (the “License”). LICENSEE may not
sublicense the rights received by it to any person, firm or entity, but shall retain LICENSOR as a distributor of the Licensed
Products on LICENSEE’S behalf as set forth in Section 8.00. The term of the License shall run for a period of eighteen
(18) months, commencing on the Effective Date (the “Term”) unless otherwise terminated in accordance with the terms
and conditions of this Agreement.

2.02 This Agreement does not convey
and shall not be construed to convey to LICENSEE any right, title to or ownership in Licensed Products derived therefrom or patent
rights, other than that specified in this Agreement.

3.00 REPRESENTATIONS AND ACKNOWLEDGMENTS

3.01. Nothing contained in this Agreement
is intended to be or shall be construed as a representation or warranty that any patent or patent application within the patent
rights relating to the Licensed Products is valid or that performance under any patent or patent application within the patent
rights is not an infringement of any patent of any other(s).

3.02. LICENSOR represents that, as of
the Effective Date of this Agreement, it has not entered any contract, license or similar agreement with a third party that restricts,
contradicts, interferes with or otherwise limits the grant of rights under this Agreement.

3.03. LICENSOR represents it has proper
authority to enter into this Agreement and to grant the rights set forth herein.

3.04. LICENSEE represents it has proper
authority to enter into this Agreement.

3.05. LICENSEE represents that it shall
use reasonable commercial efforts to market the Licensed Products from and after the Effective Date of this Agreement and shall
not favor the products it develops or licenses from third parties over the sale and marketing of the Licensed Products to its current
and prospective customers. LICENSEE further agrees that it shall retain, as reserves from the sales of Licensed Products, Outside
Products (as defined in Section 8.01), borrowings, and funds raised from the sale of equity in LICENSEE, amounts sufficient for
LICENSEE to meet its obligations under this Agreement.

4.00 PROTECTION OF INTELLECTUAL PROPERTY

4.01. If LICENSEE believes a third party
is infringing upon any patent rights of any Licensed Products during the term of such patent, LICENSEE shall notify LICENSOR, in
writing, and simultaneously shall furnish LICENSOR all information upon which LICENSEE’S belief is based.

5.00 INFRINGEMENT OF THIRD PARTY
PATENTS

5.01. LICENSEE shall promptly notify
LICENSOR, in writing, of any threat, suit or claim arising from an allegation that the manufacture, use and/or sale of Licensed
Product(s), Process(es) or Service(s) constitutes infringement of a third party’s patent in a particular country.

5.02 Upon LICENSOR’S request,
LICENSEE will render assistance for LICENSOR’S defense of such a threat, suit or claim or settlement and satisfaction thereof.

6.00 [INTENTIONALLY DELETED]

7.00 PAYMENTS, FEES AND ADDITIONAL
CONSIDERATION

7.01 LICENSEE shall pay a Quarterly
Fee to LICENSOR in accordance with the following schedule:

	Quarterly License Fee Due Date	
        Amount

	Effective Date	
        $150,000

	September 13, 2020	$50,000
	January 6, 2020	
        $200,000

	April 1, 2020	
        $300,000

	July 1, 2020	
        $300,000

	October 1, 2020	
        $250,000

	January 4, 2021	$250,000

 

7.02 As
additional consideration for LICENSOR’S grant of the License, and in further consideration of LICENSOR’S agreement
to sell the Licensed Products and other products in the Fields on behalf of LICENSEE as set forth in Section 8.00, LICENSEE agrees
as follows:

7.02.1 During the Term, LICENSEE
shall pay LICENSOR’S usual and customary operating expenses, including, without limitation, its general office overhead,
including, but not limited to, utilities, travel and entertainment, postage and rent for LICENSOR’S office located at 5450
NW 33rd Avenue, Unit 103, Fort Lauderdale, Florida 33309 (or any successor location thereto). The current rent for LICENSOR’S
office is $2,222.41 per month. LICENSEE’S obligation to pay LICENSOR’S operating expenses shall not include expenses
for LICENSOR’S personnel, including, but not limited to, LICENSOR’S principal, but LICENSEE acknowledges that personnel
retained by it may be necessary to assist the parties in the marketing, administration or the sale of Licensed Products.

7.02.2 During the Term, LICENSEE
shall pay all payments as they become due following the Effective Date on LICENSOR’S indebtedness with the Iberia Bank (the
“Iberia Loan”) (equal to $464,387.04 as of July 28, 2019) and LICENSOR’S principal debt arising from his home
equity line of credit incurred for LICENSOR’S business purposes (the “HE Loan”) (equal to $60,000 as of July
29, 2019) (collectively, the “Bank Debt”). The current monthly payment on the Iberia Loan is $4,308.47 and the monthly
payment to be paid on the HE Loan by LICENSEE IS $3,660.21. The LICENSEE recognizes and acknowledges that the terms of the Bank
Debt could change (e.g., the maturity date on the Iberia Loan is in November, 2019). In such event, LICENSEE shall have the option
to pay the loan in full or continue to pay the loan under the new terms set by the lender.

7.02.3 LICENSEE shall issue to
LICENSOR shares of LICENSEE’S stock (the “Stock”) as follows:

	Date of Issuance	Number of Shares of Stock
	At closing	1,000,000
	And 1,000,000 at the time of each license fee payment.	 

LICENSOR agrees, and shall cause
its designee, if any, to agree that the Stock will be held for investment only and not with a view to distribution. The recipient
of the Stock shall be required to hold the Stock for the periods designated by the LICENSEE to its shareholders generally and shall
comply with all restrictions imposed on the sale or distribution of the Stock by LICENSEE or as required under applicable state
and Federal law.

7.03. In the event any payment due LICENSOR
is not received when due under this section, LICENSEE shall pay a late charge of two percent (2%) of the amount due and owing (“Late
Payment Charge”). The Late Payment Charge shall be issued simultaneously with issuance of the payment due.

8.00 DISTRIBUTION ARRANGEMENT

8.01. Commencing on the Effective Date,
LICENSEE will sell LICENSOR the Licensed Products on the prices and terms per Schedule C. To the extent such sales are not from
Inventory, LICENSEE shall be responsible to pay amounts charged by the manufacturers LICENSOR has procured to manufacture the Licensed
Products. LICENSOR shall utilize its historical sales efforts, plus any new approaches approved by the parties, to market the Licensed
Products.

8.02. LICENSOR may also market products,
directly or through agents, distributors or subdistributors, in the Fields which are not Licensed Products, including products
patented or controlled by third parties, or by LICENSEE (“Outside Products”), to customers and shall remit the Net
Proceeds therefrom to LICENSOR for no additional consideration; provided, however, that for the purposes of this Section 8.02,
the definition “Net Proceeds” shall include reductions for the cost of goods sold, marketing costs not described in
Section 7.02.1 and commissions or fees paid to or on behalf of LICENSOR’S agents, distributors or subdistributors.

8.03. LICENSEE may retain other sales
agents to sell the Licensed Products and/or Outside Products to customers. LICENSOR shall receive a commission (the “Override”)
equal to ten percent (10%) of the gross proceeds therefrom. LICENSEE may utilize LICENSOR to process such sales on LICENSEE’S
behalf. The Override shall be paid within thirty (30) days following LICENSEE’S receipt of payment from the customer giving
rise to the Override and shall be accompanied by a report detailing the amount of Override.

8.04. Each party shall have the right,
one (1) time per year, to review the books and records of the other party to confirm the accuracy of the sales reported and the
payment of any amounts remitted pursuant to this Section 8.00.

9.00 SALE OF INVENTORY

9.01. In order to facilitate the sale
of Licensed Products to LICENSEE’S customers, LICENSOR herby sells, and LICENSEE hereby purchasers, LICENSEE’S entire
inventory in existence immediately prior to the Effective Date for a total purchase price of approximately $850,000 (the “Inventory”).
The final cost (excluding obsolete inventory) will be determined by the list of the inventory and costs so purchased as set forth
on Schedule B.

9.02. The purchase price for the Inventory
shall be paid by LICENSEE pursuant to a Promissory Note in the form set forth on Exhibit A delivered to LICENSOR by LICENSEE contemporaneously
with its delivery of a signed copy of this Agreement (the “Note”). The Note will provide for payment of the amount
due, plus interest at six percent (6%) per annum with the first payment due October 1, 2019, paid in eighteen (18) equal monthly
installments over the Term.

9.03. In the event the Agreement is
terminated prior to the end of the Term, any remaining unused Inventory will be returned by LICENSEE to LICENSOR and LICENSEE shall
receive credit for such returns against the balance due under the Note, in an amount equal to the cost of the Inventory so returned,
less a twenty percent (20%) restocking fee, if applicable. In the event the credit is insufficient to eliminate the remaining balance,
plus accrued, unpaid interest, due under the Note, the remaining amount shall be due and payable within thirty (30) days following
the date of termination of the Agreement. In the event the credit exceeds the amount due under the Note, LICENSOR shall pay LICENSEE
the difference within thirty (30) days following the date of termination of this Agreement.

10.00 PUBLICATIONS AND CLEARANCES

10.01. Unless required by law, the Securities
and Exchange Commission, or any other regulatory body, the LICENSEE shall not use, without the prior written consent and approval
of LICENSOR, which shall not be unreasonably withheld, the name or trademark(s) of LICENSOR or of any individual employee or division
thereof, for any commercial purposes, including, without limitation, the issuance of press releases of the disclosure of this Agreement
to LICENSEE’S prospective investors. In the event LICENSOR utilizes any of the foregoing without LICENSEE’S prior review
in the manner permitted herein, LICENSEE shall provide written notice to LICENSOR of such use and the notice will set forth in
detail the manner of the use and the basis by which LICENSEE believed it had the right to do so under this Section 10.01.

11.00 TERMINATION

 

11.01. Either party may terminate this
Agreement for fraud, willful and material misconduct or illegal conduct related to this Agreement of the other party upon written
notice to the other party. Termination for such reason shall become effective upon receipt of such written notice by the other
party.

11.02. If either party shall commit
a breach or default of any term(s) or condition(s) of this Agreement and shall also fail to correct said breach or default within
thirty (30) days after receipt of written notice thereof from the other party (ten (10) days in the case of payment breaches),
the party giving notice may, at its option and in addition to any other remedies it may have at law or in equity, terminate this
Agreement by sending written notice of termination to the other party to such effect. Upon the occurrence of a second breach of
this nature by the same party, the other party may terminate this Agreement if the said breach or default is not cured upon ten
(10) days written notice (five (5) days in the case of payment breaches). Termination under this section shall be effective as
of the date set forth in said written notice

11.03. Any failure of either party to
this Agreement to terminate hereunder shall not be of such default or breach or a waiver of any future default or breach.

11.04. Termination of this Agreement
by either party for any reason shall not affect and shall be without prejudice to the rights and obligations of the parties that
have accrued prior to the effective date of said termination.

11.05. If, during the term of this Agreement,
LICENSEE shall enter into bankruptcy or if LICENSEE’S business shall be placed in the hand of a receiver or trustee, whether
or not by a voluntary act of LICENSEE, this Agreement shall immediately terminate.

12.00 REPRESENTATIONS & WARRANTIES

12.01. DISCLAIMER OF WARRANTIES: LICENSOR
MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, ORAL OR IN WRITING, IN FACT OR ARISING
BY OPERATION OF LAW OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE REGARDING LICENSED PRODUCTS, LICENSED INFORMATION, AND PATENT RIGHTS PROVIDED TO LICENSEE HEREUNDER OR REGARDING THE OWNERSHIP
AND FREEDOM FROM INFRINGEMENT OF ANY THIRD PARTY’S RIGHTS OR INTERESTS EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT. THE
PARTIES ASSUME NO RESPONSIBILITIES WHATSOEVER OTHER THAN AS SET FORTH IN THIS AGREEMENT.

12.02. IN NO EVENT WILL LICENSOR OR
ANY OF ITS OFFICERS, EMPLOYEES OR AGENTS BE LIABLE FOR ANY INCIDENTAL, SPECIAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES INCLUDING, BUT
NOT LIMITED TO, LOSS OF ANTICIPATED PROFITS OR ECONOMIC LOSS RESULTING FROM EXERCISE OF THIS LICENSE OR MANUFACTURE, SALE, OR USE
OF LICENSED PRODUCTS, LICENSED INFORMATION, OR OTHER INFORMATION, EVEN IF LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

13.00 MISCELLANEOUS

13.01. Notice hereunder shall be deemed
sufficient if given by regular U.S. mail with return receipt requested, postage prepaid and addressed to the party to receive such
notice. Until otherwise notified in writing, all notices given or made to the parties shall be addressed as follows:

	LICENSOR	
        LICENSEE

         

	
        Spinal Resources Inc.

        Attn: Bernard Bedor

        President and Chief Executive Officer

        5450 NW 33rd Avenue, Unit 103

        Fort Lauderdale, Florida 33309
	
        Ozop Surgical Corp.

        Attn: Barry Hollander

        Chief Financial Officer

        319 Clematis Street, Suite 714

        West Palm Beach, FL 33401

         

Any Notices sent by LICENSOR and returned
because it was unclaimed or refused is deemed Notice.

13.02. This Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Agreement is nonassignable
without the written approval of LICENSOR, which will not be unreasonably withheld. LICENSOR shall be permitted to assign this Agreement
to a successor who shall have the option to accept the assignment and receive the benefits and perform the obligations of the LICENSOR
or accept the assignment and immediately terminate the Agreement following the assignment.

13.03. This Agreement may be modified
only by mutual written agreement of the parties hereto.

13.04. In the event any portion of this
Agreement shall be deemed by a court of competent jurisdiction to be overly broad in scope, duration or area of applicability,
the court, considering the same, shall have the power and is hereby authorized and directed to limit such provision so it is no
longer overly broad and to enforce the same as so limited. Subject to the foregoing sentence, in the event any provision of this
Agreement shall be held to be invalid, illegal or unenforceable for any reason, such invalidity, illegality or unenforceability
shall attach only to such provision and shall not affect or render invalid or unenforceable the remaining provisions of this Agreement.

13.05. LICENSEE shall comply with all
applicable Federal, state and local laws and regulations in connection with its activities conducted pursuant to this Agreement.

13.06. The captions and section numbers
used in this Agreement are inserted only as a matter of convenience and do not define, limit, explain or modify the scope or intent
of such sections or otherwise affect this Agreement.

13.07. This Agreement and the inventorship
and ownership of any inventions, patents, products and other intellectual property rights relating to the subject matter(s) of
this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Florida and the United
States of America.

13.08. Any term, provision or condition
required for the interpretation of this Agreement or which is necessary for the full observation and performance by each party
hereto of all rights and obligations arising prior to the date of termination shall survive such termination.

13.09. This Agreement constitutes the
entire and only agreement between the parties and all other prior negotiations, representations, agreements and understandings
are superseded hereby.

(Signature Page Follows)

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have caused their duly authorized representatives to execute this Agreement.

 

	SPINAL RESOURCES INC.
	BYBernard Bedor, President

                                                                                 

                                                                                _________________________________

                                                                                Signature

                                                                                 

                                                                                _________________________________

                                                                                Date

                                                                                 

	OZOP SURGICAL CORP.
	BYMichael
Chermak, Chief Executive Officer

                                                                                                                                            

                                                                                                                                            
 

                                                                                _________________________________

                                                                                Signature

                                                                                 

                                                                                _________________________________
 Date

 

    	 

    	 

    

Schedule A

Licensed Products

 

 

 

 

 

    	 

    	 

    

Schedule B

List of Purchased Inventory

 

 

 

 

 

    	 

    	 

    

Schedule C

Purchase Price for Licensed Products

 

To be determined at the time of each order

 

 

  

    	 

    	 

    

Exhibit A

Promissory NoteExhibit 10.2

 

OPTION
AGREEMENT

THIS OPTION AGREEMENT
(“Agreement”) is entered into as of the 23rd day of August, 2019, by and between
SPINAL RESOURCES, INC., a Florida corporation (“Optionor”) and OZOP SURGICAL CORP., a Nevada corporation (“Optionee”),
with reference to the following facts:

A. Optionor
is in the business of developing and selling products utilized in spine and related surgical procedures (the “Business”).

B. Contemporaneously
with the execution of this Agreement, the parties are entering into an Exclusive License Agreement (the “ELA”).

C. Optionor
desires to grant to Optionee an option to purchase the Business upon the terms and conditions set forth herein, and Optionee desires
to acquire such option.

NOW THEREFORE, IN
CONSIDERATION of the mutual agreements herein set forth, and other valuable consideration, receipt of which is hereby acknowledged,
the parties hereby agree as follows:

ARTICLE I

GRANT OF OPTION

In consideration
of the parties’ entering into the ELA, Optionor hereby grants to Optionee an option to purchase the Business upon all
of the terms, covenants and conditions set forth herein (the “Option”). Exercise of the Option shall require the Optionor
to sell substantially all of the Assets of the Business to Optionee, unless the parties agree that the sale shall be structured
as a sale of equity. During the term of the ELA, Optionor cannot sell the Business. As partial consideration for Optionor’s
grant of the Option, Optionee agrees that it shall not purchase, either as a purchase of stock or assets, the business of any competitor
of the Business unless it has first exercised the Option provided herein unless such purchase is materially agreed upon by Optionor.

ARTICLE II

TERM AND MANNER OF EXERCISE

2.1(a)The
Option shall be exercisable by Optionee at any time of the Term (as defined in the ELA) but prior to the end of the Term (the “Option
Period”) only by delivering to Optionee written notice of exercise to Optionor prior to the expiration of the Option Period
(the “Option Exercise Notice”). Optionee may only exercise the Option if Optionee is not in breach of the terms of
the ELA at the time of exercise of the Option.

(b)If Optionee
fails to exercise the Option on or before the expiration of the Option Period, the Option and this Agreement shall be null and
void and of no further force or effect, but Optionor shall have the right, on written notice to the Optionee (the Put Exercise
Notice” to require Optionee to purchase the Business in accordance with the terms set forth in this Agreement (the “Put”).
If Optionee timely exercises the Option, the parties shall enter into a definitive agreement for the purchase of the Business,
which shall contain the terms set forth in this Agreement, plus the usual and customary terms for transactions of this nature.
Closing of the purchase of the Business (the “Closing”) shall be thirty (30) days following the last to occur of (i)
Optionor’s receipt of the Option Exercise Notice; or (ii) Optionee’s receipt of the Put Exercise Notice.

ARTICLE III

BUSINESS PURCHASE PRICE

3.1 The
purchase price for the Business shall be determined as follows:

Optionee will
purchase the Business for a minimum purchase price of $5,500,000. The actual purchase price will be determined and shall be based
on average monthly sales of Licensed Products and Outside Products (as both terms are defined in the ELA) by or through Optionor
in accordance with the following table:

	Average Monthly Sales	Purchase Price
	 	 
	$0 - $150,000	$5,500,000
	$150,001-$250,000	$7,000,000
	$250,001 and over	$8,000,000

 

For purposes of
this computation, payments made by Optionee to or for the benefit of Optionor for the Quarterly Fee, Inventory and Bank Debt (as
all such terms are defined in the ELA), prior to Closing shall be credited against the purchase price. Sales falling under Section
8.03 of the ELA shall not be counted in the determination of the Average Monthly Sales and payment of the Override (as defined
in the ELA) shall not be credited against the purchase price.

3.2 The
purchase price computed in accordance with Section 3.1 shall be paid as follows:

(a)Seventy-five
percent (75%) of the purchase price, net of the credits set forth above, shall be paid at Closing, in cash, by wire transfer or
other immediately available funds.

(b)The
remaining balance due will be paid in equal quarterly installments with six percent (6%) interest beginning on the first day of
the second month following the month in which the Closing occurs. Payment of the amount due will be secured by Optionee’s
pledge of collateral that shall be determined prior to Closing.

ARTICLE IV

REPRESENTATIONS
AND WARRANTIES

4.1 As
an inducement to Optionor to enter into this Agreement, Optionee represents, warrants and covenants that it is a corporation duly
organized, validly existing and in good standing under the laws of its state of incorporation; that it has the corporate power
and authority to enter into this Agreement, and to consummate the transaction herein contemplated; and that the execution and delivery
hereof and the performance by Optionee of its obligations hereunder will not violate or constitute an event of default under the
terms or provisions of any agreement, document or instrument to which Optionee is a party or by which Optionee is bound.

4.2 As
an inducement to Optionee to enter into this Agreement, Optionor represents, warrants and covenants as of the date hereof as follows:

(a)Optionor
is a corporation, duly organized, validly existing and in good standing under the laws of Florida; and it has the requisite corporate
power and authority to (i) enter into this Option Agreement, and (ii) sell the Business. The execution and delivery hereof and
the performance by Optionor of its obligations hereunder will not violate or constitute an event of default under the terms and
provisions of any agreement, document or instrument to which Optionor is a party or by which Optionor is bound;

(b)This
Agreement is a valid and binding obligation of Optionor; and

(c)Optionor
has not granted any options or any other rights to acquire fee title or other interests in the Business, other than as set forth
in this Option Agreement.

4.3 The
truth, accuracy, and completeness of each of the representations, warranties and covenants of Optionee and of Optionor herein set
forth, shall constitute a condition precedent to the obligations of Optionor and Optionee, respectively, hereunder.

ARTICLE V

(intentionally omitted)

ARTICLE VI

ASSIGNMENT

Neither Optionee
nor Optionor may assign this Agreement or any of their rights hereunder for any purpose whatsoever
without the written consent of the other party (which consent shall not be unreasonably withheld by either party) and any
purported assignment shall be absolutely void and of no force or effect.

ARTICLE VII

MISCELLANEOUS

7.1 Entire
Agreement. The parties hereto with respect to the subject matter hereof, and no prior or contemporaneous written
or oral agreement or understanding pertaining to any such matter shall be effective for any purpose. No provision of this
Agreement may be amended or added to except by an agreement in writing signed by the parties hereto.

7.2 Attorneys’
Fees. Should any action be brought arising out of this Agreement, including without
limitation any action for declaratory or injunctive relief, the prevailing party shall be entitled to reasonable attorneys’
fees and costs and expenses of investigation incurred in appellate proceedings or in any action or participation in, or in connection
with, any case or proceeding under Chapter 7, 11 or 13 or the Bankruptcy Code or any successor statutes, and any judgment or decree
rendered in any such actions or proceeding shall include an award thereof.

7.3
Binding Effect. The provisions of this Agreement shall inure to the benefit of and be binding upon Optionor and Optionee
and their respective successors and permitted assigns.

7.4
No Waiver. No waiver of any of the provisions of this Agreement shall be deemed, or shall constitute, a waiver of any other
provision, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed
in writing by the party making the waiver.

7.5 Further
Acts. Each party shall, at the request of the other, execute, acknowledge (if appropriate) and deliver whatever additional
documents, and do such other acts, as may be reasonably required in order to accomplish the intent and purposes of this Agreement.

7.6 Counterparts.
This Agreement may be executed in counterparts, each of which so executed shall be deemed to be an original, and such counterparts
shall together constitute but one and the same agreement.

7.7 Amendments.
This Agreement may not be changed or modified except by an instrument in writing executed by the party asserted to be bound thereby.

7.8 Notices.
All communications, notices and demands of any kind which either party may be required or may desire to give to or serve upon the
other, shall be made in writing and delivered by personal service to any officer of the other party or sent by registered mail,
postage paid, return receipt requested, to the following addresses:

 

	To Optionor:	Spinal Resources, Inc.

Attn:  Bernard Bedor

President and Chief Executive Officer

5450 NW 33rd Avenue, Unit 103

Fort Lauderdale, Florida 33309
	To Optionee:	Ozop Surgical Corp.

Attn:  Barry Hollander

Chief Financial Officer

319 Clematis Street, Suite 714

West Palm Beach, FL 33401 

 

Any such notice sent by mail shall be
presumed to have been received by the addressee 72 hours after posting in the United States mail in ________________ County,
Florida. Either party may change its address by giving the other party written notice of its new address as herein provided.

7.9 Headings.
Any headings in this Agreement are solely for the convenience of the parties and are not part of this Agreement.

7.10 Governing
Law. This Agreement and the transaction herein contemplated shall be construed in accordance with and governed by the laws
of the State of Florida.

    	 

    	 

    

IN WITNESS WHEREOF,
Optionor and Optionee have executed this Agreement on the day and year first above written.

 

	 	
        “OPTIONEE”

        OZOP SURGICAL CORP.

        By: 
_________________________

Its: Chief Executive Officer

	 	
        “OPTIONOR”

        SPINAL RESOURCES,
        INC.

        By:  _________________________

        President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]